Premium
Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases
Author(s) -
Anderson Caleb F.,
Grimmett Maria E.,
Domalewski Christopher J.,
Cui Honggang
Publication year - 2019
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1586
Subject(s) - medicine , intensive care medicine , nanomedicine , drug delivery , disease , drug , adverse effect , pharmacology , nanotechnology , pathology , materials science , nanoparticle
Respiratory illnesses are prevalent around the world, and inhalation‐based therapies provide an attractive, noninvasive means of directly delivering therapeutic agents to their site of action to improve treatment efficacy and limit adverse systemic side effects. Recent trends in medicine and nanoscience have prompted the development of inhalable nanomedicines to further enhance effectiveness, patient compliance, and quality of life for people suffering from lung cancer, chronic pulmonary diseases, and tuberculosis. Herein, we discuss recent advancements in the development of inhalable nanomaterial‐based drug delivery systems and analyze several representative systems to illustrate their key design principles that can translate to improved therapeutic efficacy for prevalent respiratory diseases. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease